Expression of receptors for advanced glycation end products in peripheral occlusive vascular disease.

The cellular interactions of advanced glycation end products (AGEs), which have been hypothesized to contribute to the development of vascular lesions, occur, at least in part, through their binding to a novel integral membrane protein, the receptor for AGEs (RAGE). Studies of human vascular segments show that endothelial RAGE expression at the antigen and mRNA level was variable and usually at low levels in samples from healthy individuals. In contrast, patients with a range of peripheral occlusive vascular diseases, with or without underlying diabetes, demonstrated prominent enhancement of endothelial RAGE expression. Smooth muscle cells and nerves in the vessel wall showed constitutively high levels of RAGE expression that were unchanged with aging (from 1 to 92 years) or by the presence of vascular disease. These data suggest that RAGE is likely to have ligands other than AGEs, and that multiple factors in addition to AGEs impact on its expression. Taken together, our findings suggest that RAGE may contribute to the pathogenesis of a range of vascular disorders.

[1]  C. W. Scott,et al.  Glycated tau protein in Alzheimer disease: a mechanism for induction of oxidant stress. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[2]  R. Bucala,et al.  Advanced glycation end products contribute to amyloidosis in Alzheimer disease. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[3]  Y. Zou,et al.  Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. , 1994, The Journal of biological chemistry.

[4]  J. van Lunzen,et al.  Vascular origin of Kaposi's sarcoma. Expression of leukocyte adhesion molecule-1, thrombomodulin, and tissue factor. , 1994, The American journal of pathology.

[5]  R. Bucala,et al.  Immunohistochemical localization of advanced glycosylation end products in coronary atheroma and cardiac tissue in diabetes mellitus. , 1993, The American journal of pathology.

[6]  S. Gordon,et al.  Divalent cation-independent macrophage adhesion inhibited by monoclonal antibody to murine scavenger receptor , 1993, Nature.

[7]  N. Morisaki,et al.  Angiogenic effects of advanced glycation end products of the Maillard reaction on cultured human umbilical cord vein endothelial cells. , 1993, Biochemical and biophysical research communications.

[8]  A. Schmidt,et al.  Regulation of human mononuclear phagocyte migration by cell surface-binding proteins for advanced glycation end products. , 1993, The Journal of clinical investigation.

[9]  M. Portero,et al.  Mechanisms of glycation in atherogenesis. , 1993, Medical hypotheses.

[10]  S. Krungkrai,et al.  Exogenous advanced glycosylation end products induce complex vascular dysfunction in normal animals: a model for diabetic and aging complications. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[11]  Martina,et al.  Receptor-specific induction of insulin-like growth factor I in human monocytes by advanced glycosylation end product-modified proteins. , 1992, The Journal of clinical investigation.

[12]  M. Suthanthiran,et al.  Two novel rat liver membrane proteins that bind advanced glycosylation endproducts: relationship to macrophage receptor for glucose-modified proteins , 1991, The Journal of experimental medicine.

[13]  J. Baynes,et al.  Formation of pentosidine during nonenzymatic browning of proteins by glucose. Identification of glucose and other carbohydrates as possible precursors of pentosidine in vivo. , 1991, The Journal of biological chemistry.

[14]  S. Ogawa,et al.  Advanced protein glycosylation induces transendothelial human monocyte chemotaxis and secretion of platelet-derived growth factor: role in vascular disease of diabetes and aging. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[15]  L. Moldawer,et al.  Macrophage/monocyte receptor for nonenzymatically glycosylated protein is upregulated by cachectin/tumor necrosis factor. , 1989, The Journal of clinical investigation.

[16]  H. Gerlach,et al.  Endothelial receptor-mediated binding of glucose-modified albumin is associated with increased monolayer permeability and modulation of cell surface coagulant properties , 1989, The Journal of experimental medicine.

[17]  K. Manogue,et al.  Cachectin/TNF and IL-1 induced by glucose-modified proteins: role in normal tissue remodeling. , 1988, Science.

[18]  A. Cerami,et al.  Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. , 1988, The New England journal of medicine.

[19]  C. Elmets,et al.  Relation between complications of type I diabetes mellitus and collagen-linked fluorescence. , 1986, The New England journal of medicine.